Pallas Health Review

Pallas Health: one all-in price, billed every 4 weeks

Pallas Health sells compounded semaglutide and tirzepatide at a price that does not move when your dose does, and it also dispenses brand-name Wegovy (pen or pill), Foundayo, Zepbound, Ozempic and Mounjaro for cash. The homepage leads with “First month from $139.” That number is real. After the first month, a compounded plan renews every 4 weeks until you cancel. That is close to monthly, but not quite.

How the pricing works, and what to watch for

Compounded semaglutide is $139 for the first month. After that, Pallas charges $199 (per 4 weeks) every 4 weeks. Tirzepatide has the same shape: $179 for the first month, then $299 every 4 weeks. Both figures are all-in. Pallas's own wording is “Provider visits, follow-ups and messaging included — no membership fee,” and shipping is free on every plan.

Two things to keep in mind. A 4-week cycle comes around 13 times a year, not 12, so over a calendar year the plan costs about eight percent more than the per-charge price suggests. A 48-week annual plan lowers the average on both drugs by sixty dollars a month, but it is charged in full once you are prescribed. Against a category median of about $182, the standing semaglutide plan sits above the middle. The consult, the check-ins and the shipping are already inside that number.

How we get the market median: $182 is the middle value of each program's lowest listed ongoing monthly price for compounded semaglutide (month to month, not a first-month promo, a prepaid plan or a price with a membership on top), across the 118 programs that publish one.

Nothing is charged at checkout. Since September 2026, Pallas saves your card and charges only once a clinician prescribes; if the clinician declines, you pay nothing. Once a prescription is issued, though, the order is final and “the current cycle isn't prorated or refunded” from then on. There is a separate “6-month promise” as well. Stay on a paid plan for six continuous months and log your doses, check-ins and weights. If you're then unhappy, or lost no net weight, you can ask within 30 days for those six months of plan payments back. One claim per patient.

Medications and the dose ladder

The compounded plans are mainly weekly injections of semaglutide or tirzepatide, and the flat price holds at every step: “your compounded plan costs the same at every dose.” Pallas does not publish a compounded dose ladder on the treatment page itself. Its blog walks the standard semaglutide climb of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg, and the Zepbound page lists a 2.5 mg starting dose increased every four weeks up to 15 mg.

• Compounded semaglutide: $139 for the first month, then $199 (per 4 weeks) every 4 weeks
• Compounded tirzepatide: $179 for the first month, then $299 every 4 weeks
• Brand-name tablets: the Wegovy pill and Foundayo are each $299 for the first month, then $499 every 4 weeks
• Brand-name pens: Zepbound is $1,069 a month for a 28-day supply; Ozempic is $1,299, and Wegovy and Mounjaro are $1,349
• No insurance routing on any of it. Pallas is cash-pay, with an itemized receipt for FSA or HSA claims

Compounded semaglutide is now also advertised as a daily tablet, but no tablet price is published. Pallas also sells NAD+, sermorelin, glutathione and women's hormone therapy from the same account, none of which this review covers.

What the intake asks, and where it stops you

“Start your visit” opens a four-stage flow labeled About you, Health, Your plan and Checkout. The first screens are light: your weight-loss goal in four ranges, a readiness question, whether you've taken a GLP-1 in the past month and which one, then height and weight with your BMI computed on the spot. The fifth screen asks for your date of birth, and from there the flow moves into personal details. So the plan-and-price step sits behind your identity, but the prices it shows are the same ones printed on the treatment page.

In 43 states the visit is fully asynchronous, with no video call. Seven states plus Washington, D.C. require one live video visit before a prescription: Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota and West Virginia. Refills are not automatic. The disclosures page says “each renewal involves clinician review of progress and tolerability.” The treatment page says “SHIPS IN ~1 WEEK,” and the brand pages say most orders arrive within about a week of approval. Pay-over-time is offered at checkout. Support is by message, a weekday phone line, or a free app that tracks doses and refills.

Trust and safety: an unusually complete disclosure page

Most cash-pay compounding sites tell you nothing about who prescribes or dispenses. Pallas publishes a clinical disclosures page, last updated in October 2026, that names its clinical partner (Lion MD) and its clinical-operations platform (CareValidate). It lists two advising physicians with NPI numbers you can look up in the federal NPI database. It names seven partner pharmacies with phone numbers: Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub, Foothills and Evoluciona Pharma. Pallas says it does this because Massachusetts, Rhode Island and Vermont rules require it. It accepts patients in all 50 states plus D.C. A LegitScript seal in the footer is issued for the Pallas domain, and there are no FDA warning letters against Pallas or its operator, Brentmoor, Inc.

A few things don't line up. The homepage claims “200,000+ patients” while the disclosures page describes a July 2026 launch and “existing waitlist patients.” The “4.8/5.0 from 2,400+ member reviews” badge doesn't link to where those reviews live. And the footer admits that “Some content on this site is AI-generated.” On the medication itself, Pallas is plain: compounded semaglutide and tirzepatide are not FDA-approved and are not generic versions of the brand-name drugs.

Who should choose it, and who should skip it

Choose Pallas if you want a flat price that includes the consult and shipping, you can budget for a charge every 4 weeks, and you care about knowing which pharmacy and which clinicians are behind your order. The named pharmacies and the NPI numbers are an advantage in this segment.

Skip it if you want billing on a true calendar month; the 4-week cycle adds a thirteenth charge each year. Get Thin MD, also flat-priced, quotes its compounded plans per month instead. Skip it if you want a refund window after your prescription is issued, because there isn't one outside the six-month promise. And skip it if you want a low-dose “microdose” line, which Pallas doesn't offer. Pallas also bills automatically every cycle, whereas Kin Meds has no auto-subscribe and lets you pick each 30- or 90-day supply.

Bottom line

Pallas Health pairs an ordinary compounded price with an extraordinary amount of disclosure. The first-month rate is real, the flat-at-every-dose promise is written on the site, and the charge-only-when-prescribed checkout removes the usual risk of paying before a clinician looks at you. Go in knowing that the bill is a 4-week charge, that it adds up to a bit more per year than twelve monthly payments, and that once the prescription is written the money doesn't come back. For a cash-pay patient who wants to know exactly who is prescribing and dispensing, it belongs on the shortlist. See how these factors are weighed in our scoring methodology.